Literature DB >> 20074607

The use of C(av) rather than AUC in safety assessment.

D A Smith1, P Morgan, W M Vogel, D K Walker.   

Abstract

Toxicokinetic data have traditionally been presented as maximum observed plasma concentrations (C(max)) and area under the concentration time curve (AUC) values. These values have been used to compare exposures across studies and species to provide valuable interpretation of drug safety data. Increasingly, questions are asked of toxicology studies to more accurately describe the concentration effect relationships in terms of compound affinity for target and off-target receptors. C(max) values can immediately be referenced to known pharmacological activities, particularly when the extent of plasma protein binding is taken into account. This provides a measure of the more pharmacologically relevant free drug exposure. AUC values on the other hand contain the component of time, which means that direct comparison to pharmacological activity values are not immediately possible. Conversion of AUC to average plasma concentration (C(av)) provides a simple and convenient means to allow such a comparison without losing any information imparted by AUC values. In this paper, the benefit and advantage of applying C(av) values is illustrated using examples taken from the literature. (c) 2010 Elsevier Inc. All rights reserved.

Mesh:

Substances:

Year:  2010        PMID: 20074607     DOI: 10.1016/j.yrtph.2010.01.001

Source DB:  PubMed          Journal:  Regul Toxicol Pharmacol        ISSN: 0273-2300            Impact factor:   3.271


  3 in total

Review 1.  The determination and interpretation of the therapeutic index in drug development.

Authors:  Patrick Y Muller; Mark N Milton
Journal:  Nat Rev Drug Discov       Date:  2012-08-31       Impact factor: 84.694

2.  Quantifying the relationship between inhibition of VEGF receptor 2, drug-induced blood pressure elevation and hypertension.

Authors:  Teresa Collins; Kelly Gray; Michal Bista; Matt Skinner; Christopher Hardy; Haiyun Wang; Jerome T Mettetal; Alexander R Harmer
Journal:  Br J Pharmacol       Date:  2018-01-18       Impact factor: 8.739

3.  A long-duration dihydroorotate dehydrogenase inhibitor (DSM265) for prevention and treatment of malaria.

Authors:  Margaret A Phillips; Julie Lotharius; Kennan Marsh; John White; Anthony Dayan; Karen L White; Jacqueline W Njoroge; Farah El Mazouni; Yanbin Lao; Sreekanth Kokkonda; Diana R Tomchick; Xiaoyi Deng; Trevor Laird; Sangeeta N Bhatia; Sandra March; Caroline L Ng; David A Fidock; Sergio Wittlin; Maria Lafuente-Monasterio; Francisco Javier Gamo Benito; Laura Maria Sanz Alonso; Maria Santos Martinez; Maria Belen Jimenez-Diaz; Santiago Ferrer Bazaga; Iñigo Angulo-Barturen; John N Haselden; James Louttit; Yi Cui; Arun Sridhar; Anna-Marie Zeeman; Clemens Kocken; Robert Sauerwein; Koen Dechering; Vicky M Avery; Sandra Duffy; Michael Delves; Robert Sinden; Andrea Ruecker; Kristina S Wickham; Rosemary Rochford; Janet Gahagen; Lalitha Iyer; Ed Riccio; Jon Mirsalis; Ian Bathhurst; Thomas Rueckle; Xavier Ding; Brice Campo; Didier Leroy; M John Rogers; Pradipsinh K Rathod; Jeremy N Burrows; Susan A Charman
Journal:  Sci Transl Med       Date:  2015-07-15       Impact factor: 17.956

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.